Biogen’s Increase of its stake in Samsung BioLogics up to 49.9%

In Brazil, Demarest advised on the antitrust clearing procedure. Biogen (Nasdaq:BIIB) has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti.

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here